Endothelial Rictor is crucial for midgestational development and sustained and extensive FGF2-induced neovascularization in the adult
暂无分享,去创建一个
M. Hall | E. Battegay | P. Limani | R. Humar | E. Haas | N. Lindenblatt | Ina Kalus | F. Aimi | Stavroula Georgiopoulou | F. Lehner | Alica Hegglin | Vinicius Gomes de Lima | Markus A. Rüegg | M. Hall
[1] S. Khaliq,et al. Involvement of vascular endothelial growth factor (VEGF) gene polymorphism in hepatocellular carcinoma of HCV patients from local population , 2017 .
[2] A. Józkowicz,et al. Cellular and molecular mechanisms of inflammation‐induced angiogenesis , 2015, IUBMB life.
[3] Christopher C W Hughes,et al. A role for partial endothelial-mesenchymal transitions in angiogenesis? , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[4] Dana M. Brantley-Sieders,et al. Regulation of Endothelial Cell Proliferation and Vascular Assembly through Distinct mTORC2 Signaling Pathways , 2015, Molecular and Cellular Biology.
[5] J. Pratap,et al. Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells , 2014, Breast Cancer Research.
[6] L. Zimmerli,et al. Rictor in Perivascular Adipose Tissue Controls Vascular Function by Regulating Inflammatory Molecule Expression , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[7] P. Leung,et al. Fibroblast Growth Factor 2 Induces E-Cadherin Down-Regulation via PI3K/Akt/mTOR and MAPK/ERK Signaling in Ovarian Cancer Cells , 2013, PloS one.
[8] S. Dedhar,et al. Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial–mesenchymal transition (EMT) , 2013, Oncogene.
[9] G. Christofori,et al. Sprouty2 expression controls endothelial monolayer integrity and quiescence , 2013, Angiogenesis.
[10] R. Kalluri,et al. Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. , 2012, Seminars in cancer biology.
[11] E. Battegay,et al. Loss of Pim1 Imposes a Hyperadhesive Phenotype on Endothelial Cells , 2012, Cellular Physiology and Biochemistry.
[12] D. Medici,et al. The role of endothelial‐mesenchymal transition in heterotopic ossification , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] H. Moch,et al. Tumor Cell Plasticity and Angiogenesis in Human Melanomas , 2012, PloS one.
[14] James W. Smyth,et al. TGF-β-induced activation of mTOR complex 2 drives epithelial–mesenchymal transition and cell invasion , 2012, Journal of Cell Science.
[15] J. Ward,et al. The Utility of Immunohistochemistry for the Identification of Hematopoietic and Lymphoid Cells in Normal Tissues and Interpretation of Proliferative and Inflammatory Lesions of Mice and Rats , 2012, Toxicologic pathology.
[16] R. Muschel,et al. Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. , 2012, Cancer research.
[17] T. Kishimoto,et al. Turn motif phosphorylation negatively regulates activation loop phosphorylation in Akt , 2011, Oncogene.
[18] P. Giovanoli,et al. In vivo visualization of the origination of skin graft vasculature in a wild-type/GFP crossover model. , 2011, Microvascular research.
[19] Lei Xu,et al. Normalization of the vasculature for treatment of cancer and other diseases. , 2011, Physiological reviews.
[20] D. McDonald,et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. , 2011, Cancer research.
[21] Jennifer L. Doyle,et al. Identification of a mechanism underlying regulation of the anti-angiogenic forkhead transcription factor FoxO1 in cultured endothelial cells and ischemic muscle. , 2011, The American journal of pathology.
[22] Yanlei Ma,et al. The relationship between early embryo development and tumourigenesis , 2010, Journal of cellular and molecular medicine.
[23] M. Iruela-Arispe,et al. Vascular remodeling of the vitelline artery initiates extravascular emergence of hematopoietic clusters. , 2010, Blood.
[24] S. Krane,et al. Stromal regulation of vessel stability by MMP14 and TGFβ , 2010, Disease Models & Mechanisms.
[25] H. Kleinman,et al. In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract , 2010, Nature Protocols.
[26] R. Kalluri,et al. Conversion of vascular endothelial cells into multipotent stem-like cells , 2010, Nature Medicine.
[27] V. Arruda,et al. Dual gene transfer of fibroblast growth factor-2 and platelet derived growth factor-BB using plasmid deoxyribonucleic acid promotes effective angiogenesis and arteriogenesis in a rodent model of hindlimb ischemia. , 2009, Translational research : the journal of laboratory and clinical medicine.
[28] Peter Carmeliet,et al. Mechanisms of Vessel Branching: Filopodia on Endothelial Tip Cells Lead the Way , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[29] D. Guertin,et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.
[30] M. Menger,et al. A New Model for Studying the Revascularization of Skin Grafts In Vivo: The Role of Angiogenesis , 2008, Plastic and reconstructive surgery.
[31] E. Casanova,et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. , 2008, Cell metabolism.
[32] J. Auwerx,et al. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. , 2008, Cell metabolism.
[33] C. Schnell,et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. , 2008, Cancer research.
[34] K. Inoki,et al. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling , 2008, The EMBO journal.
[35] Daniela Gabriel,et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.
[36] Elizabeth D. Wederell,et al. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. , 2008, Cancer research.
[37] Thomas D. Schmittgen,et al. Real-time PCR quantification of precursor and mature microRNA. , 2008, Methods.
[38] M. Guba,et al. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis , 2007, Cancer and Metastasis Reviews.
[39] C. Ruhrberg,et al. Selective requirements for NRP1 ligands during neurovascular patterning , 2007, Development.
[40] R. Behringer,et al. Staining Whole Mouse Embryos for {beta}-Galactosidase (lacZ) Activity. , 2007, CSH protocols.
[41] S. Cohen,et al. Re-evaluating AKT regulation: role of TOR complex 2 in tissue growth. , 2007, Genes & development.
[42] E. Hofer,et al. Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis , 2007, Thrombosis and Haemostasis.
[43] M. Hall,et al. Hypoxia-Induced Endothelial Proliferation Requires Both mTORC1 and mTORC2 , 2007, Circulation research.
[44] D. Guertin,et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. , 2006, Developmental cell.
[45] Jackelyn A. Alva,et al. VE‐cadherin‐CreERT2 transgenic mouse: A model for inducible recombination in the endothelium , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.
[46] J. Qin,et al. SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity , 2006, Cell.
[47] J. Woo,et al. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. , 2006, Developmental cell.
[48] H. Kawamura,et al. Signal transduction in endothelial cells by the angiogenesis inhibitor histidine-rich glycoprotein targets focal adhesions. , 2006, Experimental cell research.
[49] D. Sabatini,et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.
[50] P. Carmeliet,et al. VE‐Cadherin‐Cre‐recombinase transgenic mouse: A tool for lineage analysis and gene deletion in endothelial cells , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.
[51] D. Sabatini,et al. Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.
[52] P. Dell’Era,et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.
[53] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[54] M. Medina,et al. Angiogenesis and signal transduction in endothelial cells , 2004, Cellular and Molecular Life Sciences CMLS.
[55] S. Kiselev,et al. Molecular Mechanisms of Tumor Angiogenesis , 2003, Biochemistry (Moscow).
[56] R. Auerbach,et al. The sponge/Matrigel angiogenesis assay , 2004, Angiogenesis.
[57] W. Gerald,et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. , 2003, Cancer cell.
[58] Jeffrey Malik,et al. Circulation is established in a stepwise pattern in the mammalian embryo. , 2003, Blood.
[59] K. Inoki,et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.
[60] P. Marie,et al. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. , 2002, Genes & development.
[61] T. Resink,et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) ‐dependent signaling , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] A. Copp,et al. Blocking endogenous FGF-2 activity prevents cranial osteogenesis. , 2002, Developmental biology.
[63] G. Koehl,et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.
[64] C. Dani,et al. Impaired ossification in mice lacking the transcription factor Sp3 , 2001, Mechanisms of Development.
[65] L. Claesson‐Welsh,et al. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. , 2001, Trends in pharmacological sciences.
[66] Nobuyuki Itoh,et al. Fibroblast growth factors , 2001, Genome Biology.
[67] K. Claffey,et al. Fibroblast Growth Factor 2 Activation of Stromal Cell Vascular Endothelial Growth Factor Expression and Angiogenesis , 2001, Laboratory Investigation.
[68] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[69] T. Mohr,et al. Evidence for a role of FGF‐2 and FGF receptors in the proliferation of non‐small cell lung cancer cells , 1999, International journal of cancer.
[70] P. Davol,et al. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: Characterizing and circumventing mechanisms of tumor resistance , 1999, The Prostate.
[71] M. Sabbieti,et al. Parathyroid Hormone Regulates the Expression of Fibroblast Growth Factor‐2 mRNA and Fibroblast Growth Factor Receptor mRNA in Osteoblastic Cells , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[72] Y. Takai,et al. Immunohistochemical study of fibroblast growth factor-2 (FGF-2) and fibroblast growth factor receptor (FGF-R) in experimental squamous cell carcinoma of rat submandibular gland. , 1999, Oral oncology.
[73] Daniel B. Rifkin,et al. Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis , 1998, The Journal of cell biology.
[74] M. Tsuneyoshi,et al. Expressions of basic fibroblast growth factor and fibroblast growth factor receptor mRNA in soft tissue tumors by in situ hybridization. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[75] M. Ittman,et al. Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. , 1997, The Journal of urology.
[76] D. Birnbaum,et al. Expression of FGF1 and FGFR1 in human melanoma tissues , 1996, Melanoma research.
[77] M. Tsuneyoshi,et al. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma , 1995, The Journal of pathology.
[78] R. Florkiewicz,et al. Quantitative export of FGF‐2 occurs through an alternative, energy‐dependent, non‐ER/Golgi pathway , 1995, Journal of cellular physiology.
[79] Cord Sunderkötter,et al. Macrophages and angiogenesis , 1994, Journal of leukocyte biology.
[80] M. Klagsbrun,et al. Purification of cartilage-derived growth factor by heparin affinity chromatography. , 1985, The Journal of biological chemistry.